Last reviewed · How we verify
isatuximab SAR650984 SC
At a glance
| Generic name | isatuximab SAR650984 SC |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ELISA in Relapsed/Refractory MM (PHASE2)
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE2)
- Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis (PHASE1)
- SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM (PHASE3)
- Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) (PHASE1)
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab (PHASE2)
- Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA) (PHASE2)
- A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- isatuximab SAR650984 SC CI brief — competitive landscape report
- isatuximab SAR650984 SC updates RSS · CI watch RSS
- Sanofi portfolio CI